Depression, social support, and beta-adrenergic transcription control in human ovarian cancer.

TitleDepression, social support, and beta-adrenergic transcription control in human ovarian cancer.
Publication TypeJournal Article
Year of Publication2009
AuthorsLutgendorf SK, DeGeest K, Sung CY, Arevalo JM, Penedo F, Lucci J, Goodheart M, Lubaroff D, Farley DM, Sood AK, Cole SW
JournalBrain Behav Immun
Volume23
Issue2
Pagination176-83
Date Published2009 Feb
ISSN1090-2139
KeywordsActivating Transcription Factors, Adult, Aged, Aged, 80 and over, Chromatography, High Pressure Liquid, Cyclic AMP Response Element-Binding Protein, Depression, Female, Gene Expression Regulation, Neoplastic, Humans, Middle Aged, Neoplasms, NF-kappa B, Norepinephrine, Oligonucleotide Array Sequence Analysis, Ovarian Neoplasms, Reverse Transcriptase Polymerase Chain Reaction, Risk Factors, Social Support, Transcription, Genetic
Abstract

Motivated by previous indications that beta-adrenergic signaling can regulate tumor cell gene expression in model systems, we sought to determine whether similar dynamics occur in primary human ovarian cancer. DNA microarray analyses of 10 ovarian carcinomas identified 266 human transcripts that were differentially expressed in tumors from patients with elevated biobehavioral risk factors (high depressive symptoms and low social support) relative to grade- and stage-matched tumors from low-risk patients. Promoter-based bioinformatic analyses indicated increased activity of several beta-adrenergically-linked transcription control pathways, including CREB/ATF, NF-kappaB/Rel, STAT, and Ets family transcription factors. Consistent with increased beta-adrenergic signaling, high biobehavioral risk patients also showed increased intra-tumor concentrations of norepinephrine (but no difference in plasma norepinephrine). These data show that genome-wide transcriptional profiles are significantly altered in tumors from patients with high behavioral risk profiles, and they identify beta-adrenergic signal transduction as a likely mediator of those effects.

DOI10.1016/j.bbi.2008.04.155
Alternate JournalBrain Behav. Immun.
PubMed ID18550328
PubMed Central IDPMC2677379
Grant ListR01 CA104825 / CA / NCI NIH HHS / United States
R01 CA109298 / CA / NCI NIH HHS / United States
R01 CA109298 / CA / NCI NIH HHS / United States
R01 CA109298-05 / CA / NCI NIH HHS / United States
R01 CA110793 / CA / NCI NIH HHS / United States
R01 CA110793 / CA / NCI NIH HHS / United States
R01 CA110793-05 / CA / NCI NIH HHS / United States
R01 CA116778 / CA / NCI NIH HHS / United States
R01 CA116778 / CA / NCI NIH HHS / United States
R01 CA116778-01A2 / CA / NCI NIH HHS / United States
R01 CA116778-02 / CA / NCI NIH HHS / United States
R01 CA116778-03 / CA / NCI NIH HHS / United States
R21 CA88293 / CA / NCI NIH HHS / United States